Dominika Piasecka
Overview
Explore the profile of Dominika Piasecka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gorska-Arcisz M, Popeda M, Braun M, Piasecka D, Nowak J, Kitowska K, et al.
Cell Mol Biol Lett
. 2024 May;
29(1):71.
PMID: 38745155
Background: Genetic abnormalities in the FGFR signalling occur in 40% of breast cancer (BCa) patients resistant to anti-ER therapy, which emphasizes the potential of FGFR-targeting strategies. Recent findings indicate that...
2.
Braun M, Piasecka D, Sadej R, Romanska H
Br J Cancer
. 2024 Apr;
131(1):11-22.
PMID: 38627607
Breast cancer (BCa) is a complex and heterogeneous disease, with different intrinsic molecular subtypes that have distinct clinical outcomes and responses to therapy. Although intrinsic subtyping provides guidance for treatment...
3.
Mieczkowski K, Kitowska K, Braun M, Galikowska-Bogut B, Gorska-Arcisz M, Piasecka D, et al.
Mol Oncol
. 2022 Jun;
16(15):2823-2842.
PMID: 35726195
We have recently demonstrated that fibroblast growth factor receptor 2 (FGFR2)-mediated signalling alters progesterone receptor (PR) activity and response of oestrogen receptor α (ER)-positive (ER+) breast cancer (BCa) cell lines...
4.
Solek J, Chrzanowski J, Cieslak A, Zielinska A, Piasecka D, Braun M, et al.
Biomedicines
. 2022 May;
10(5).
PMID: 35625798
Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS)...
5.
The diagnostic challenge in pulmonary tumour embolism in cancer: a case report and literature review
Zielinska A, Braun M, Piasecka D, Minc P, Romanska H
Contemp Oncol (Pozn)
. 2021 Feb;
24(4):258-262.
PMID: 33531874
Pulmonary tumour embolism is a rare condition without specific symptoms or pathognomonic features. Pulmonary tumour embolism can occur as the first manifestation of cancer, but because of diagnostic difficulties, it...
6.
Braun M, Piasecka D, Bobrowski M, Kordek R, Sadej R, Romanska H
Diagnostics (Basel)
. 2020 Dec;
10(12).
PMID: 33297384
We present here an assessment of a 'real-life' value of automated machine learning algorithm (AI) for examination of immunohistochemistry for fibroblast growth factor receptor-2 (FGFR2) in breast cancer (BC). Expression...
7.
Piasecka D, Braun M, Mieszkowska M, Kowalczyk L, Kopczynski J, Kordek R, et al.
Neoplasia
. 2020 Sep;
22(11):576-589.
PMID: 32980776
There are data to suggest that some ductal carcinoma in situ (DCIS) may evolve through an evolutionary bottleneck, where minor clones susceptible to the imposed selective pressure drive disease progression....
8.
Braun M, Piasecka D, Tomasik B, Mieczkowski K, Stawiski K, Zielinska A, et al.
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32971804
Interaction between fibroblast growth factor receptor 2 (FGFR2) and estrogen/progesterone receptors (ER/PR) affects resistance to anti-ER therapies, however the prognostic value of FGFR2 in breast cancer (BCa) remains largely unexplored....
9.
Kowalczyk L, Braun M, Tomasik B, Piasecka D, Michno D, Fijuth J, et al.
Contemp Oncol (Pozn)
. 2019 Jul;
23(2):121-125.
PMID: 31316296
Ossifying fasciitis is a very rare disease of reactive character; however, it can mimic malignant lesions, especially osteosarcoma. We report a case of a 30-year-old woman, who experienced a rapidly...
10.
Piasecka D, Braun M, Kitowska K, Mieczkowski K, Kordek R, Sadej R, et al.
J Exp Clin Cancer Res
. 2019 May;
38(1):230.
PMID: 31142340
Stromal stimuli mediated by growth factor receptors, leading to ligand-independent activation of steroid hormone receptors, have long been implicated in development of breast cancer resistance to endocrine therapy. Mutations in...